Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration.

Ian J Constable,Cora M Pierce,Chooi-May Lai,Aaron L Magno,Mariapia A Degli-Esposti,Martyn A French,Ian L McAllister,Steve Butler,Samuel B Barone,Steven D Schwartz,Mark S Blumenkranz,Elizabeth P Rakoczy

EBioMedicine（2016）

引用 122|浏览11

暂无评分

摘要

•Subretinal injection of rAAV.sFLT-1 was found to be safe in 21 patients with wet age-related macular degeneration.•Visual acuity was maintained in gene therapy treated patients over the 52week period.•The gene therapy treated group of patients had a trend towards fewer ranibizumab retreatments than the control group.

查看译文

关键词

Wet age related macular degeneration,AAV.sFLT-1,Gene therapy,Clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要